In the BioHarmony Drug Report Database

"Preview" Icon

Chlorpromazine

Thorazine (chlorpromazine) is a small molecule pharmaceutical. Chlorpromazine was first approved as Thorazine on 1982-01-01. It is used to treat acute intermittent porphyria, anxiety disorders, attention deficit and disruptive behavior disorders, child behavior disorders, and hiccup amongst others in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A. In addition, it is known to target D(2) dopamine receptor, 5-hydroxytryptamine receptor 6, D(3) dopamine receptor, 5-hydroxytryptamine receptor 7, D(1B) dopamine receptor, alpha-2A adrenergic receptor, D(4) dopamine receptor, histamine H1 receptor, alpha-2C adrenergic receptor, alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 1A, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 2C, short transient receptor potential channel 5, and gamma-aminobutyric-acid receptor subunit beta.

 

Trade Name

 

Thorazine
 

Common Name

 

chlorpromazine
 

ChEMBL ID

 

CHEMBL71
 

Indication

 

acute intermittent porphyria, anxiety disorders, attention deficit and disruptive behavior disorders, child behavior disorders, hiccup, nausea, psychotic disorders, schizophrenia, tetanus, vomiting
 

Drug Class

 

Typical antipsychotic

Image (chem structure or protein)

Chlorpromazine structure rendering